title: Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
authors.forename: Rym Benmously
authors.initials: RB
authors.lastname: Mlika
authors.forename: Nadia
authors.initials: N
authors.lastname: Kerkeni
authors.forename: Hayet
authors.initials: H
authors.lastname: Marrak
authors.forename: Samy
authors.initials: S
authors.lastname: Fenniche
authors.forename: Inçaf
authors.initials: I
authors.lastname: Mokhtar
authors.forename: Achraf
authors.initials: A
authors.lastname: Debbiche
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D044383:Black People; D003875:Drug Eruptions / Q000209:etiology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D014059:Tongue / Q000473:pathology*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a